Indeed. SHPG CEO says "We are firing on all cylinders". Great company.
@@@@The launch of the first drug to treat binge eating disorder helped Shire post a better-than-expected 20 percent rise in first-quarter earnings on Thursday. The launch of the first drug to treat binge eating disorder helped Shire post a better-than-expected 20 percent rise in first-quarter earnings on Thursday. Shire received approval to use Vyvanse, an amphetamine widely prescribed to treat hyperactivity, for an eating disorder only officially recognised in the United States two years ago. Sales of Vyvanse increased by 17 percent to $417 million (£271.3 million), Shire said on Thursday.Shire said a good performance by Cinryze, a treatment for hereditary angioedema, also contributed to the 20 percent jump in post non-GAAP earnings per share of $2.84, beating a market consensus of $2.60. "We are firing on all cylinders," Ornskov said. "We are very satisfied with the progress we've made."
Shire is trading on the LSE at 5450 pence today
@@@@Shire : *S&P CAPITAL IQ RAISES SHIRE PRICE TARGET TO 6100 PENCE - 'BUY'
04/30/2015 | 09:39am US/Eastern
More turd flinging today. So far we have ACOR, SHPG, JAZZ, PCYC/ABBV, BIIB, and CELG. Apparently he will be filing challenges to a total of 15 patents. The first of these will be coming up for review starting late summer, then six months after that rulings.
@@@The effects so far of the patent challenges brought by Dallas hedge fund manager Kyle Bass to big drug companies in the past few days have apparently been non-existent. Since the group Bass founded earlier this year, dubbed “The Coalition for Affordable Drugs,” filed a challenge yesterday to a patent owned by the state’s largest locally-based drugmaker, Biogen (Nasdaq: BIIB), it has filed two more. One is against a patent held by New Jersey-based Celgene (Nasdaq: CELG) for its multiple myeloma drug, Thalomid, and the other takes aim at another Massachusetts company, Shire Pharmaceuticals (Nasdaq: SHPG), and its drug for short bowel syndrome, Gattex. Bass announced his intentions earlier this year to file a total of 15 such patent challenges through a three-year-old process at the U.S. Patent and Trademark Office called the inter partes review, or IPR. He has now filed nine.
I think he is flinging shiiatt at the wall with the hope that some it it sticks.
@@@@Pharmacyclics, Inc. (NASDAQ: PCYC) fell victim Monday to the latest patent challenge by hedge fund manager and short seller Kyle Bass. AbbVie Inc (NYSE: ABBV) agreed last month to acquire Pharmacyclics for $21 billion. Dallas-based Hayman Capital Management L.P., managed by Bass, challenged one of Pharmacyclics' patents on Imbruvica, as treatment for mantle cell lymphoma.The Imbruvica challenge is the latest for Bass, who has mounted similar objections so far to patents held by Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Acorda Therapeutics Inc. (NASDAQ: ACOR) and Shire PLC (NASDAQ: SHPG).
Hard to believe it's just this. Not sure why the FDA gave the NDA priority, given there's already drugs for this out there and the SHPG drug did not have great results in the latest trial.
@@@@Shire (NASDAQ:SHPG) stock popped nearly 3% Thursday after the specialty drugmaker said the FDA had granted priority review to its dry-eye treatment lifitegrast. Shire said the FDA had set a deadline of Oct. 25 to make a decision on the product, which apparently was sooner than many investors had expected. The phase-three trials for the drug produced mixed results, which some analysts doubted would be sufficient for approval. In December, Leerink analyst Jason Gerberry modeled a 2017 launch for lifitegrast, saying that "first-pass approval looks challenging." Dry-eye disease is a fairly common disorder typically treated with Restasis, a product sold by Allergan before it was acquired last month by Actavis (NYSE:ACT). Restasis is a topical form of the old immunosuppressant drug cyclosporin, while lifitegrast is a new product developed by SARcode, which Shire acquired in 2013.
What makes you think he even has one? My understanding is this is a strategy he has adopted after the USPTO recently provided patent fighters the option of using an IPR (Inter Partes Review) procedure.
FDA approved an NDA and priority review on an SHPG dry eye disease drug.
@@@@@LEXINGTON, Massachusetts, April 9, 2015 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lifitegrast and granted a Priority Review designation. Lifitegrast is an investigational treatment for dry eye disease in adults and, if approved, has the potential to be the first treatment indicated to address both signs and symptoms of the disease. The FDA is expected to provide a decision on October 25, 2015, based on the Prescription Drug User Fee Act V action date. The FDA grants Priority Review designation to drugs that have the potential to provide significant improvements in the safety or effectiveness for the treatment, diagnosis or prevention of a serious disease. Drugs with Priority Review designation have an accelerated review target of eight months, instead of the standard of 12 months
Will this turn out to be another fishing tale about a nice one that got away or will the fisherman come home with a nice catch?
@@@@April 08--The stock of San Rafael-based BioMarin Pharmaceutical Inc. spiked at the end of March following a report that Shire PLC, a biopharmaceutical company based in Ireland, is seeking to acquire it. Ben Harrington, a former mergers and acquisition editor at the Daily Telegraph who now writes for the blog Betaville, broke the news on March 26. Harrington wrote, "top sources (and I mean top)" had told him that "Shire has set its sights on combining with BioMarin." Harrington wrote that Shire had recently approached BioMarin about a deal "although it's not clear whether things have progressed further." In his post, Harrington also said that BioMarin had also engaged financial advisers "to defend the company from a larger predator." Harrington added that 18 months ago Swiss pharmaceutical giant Roche "took a good look at BioMarin." Founded in Novato in 1997, BioMarin specializes in the development and production of "orphan drugs," or medications that treat rare diseases. In January 2012, BioMarin moved its headquarters to downtown San Rafael and in 2013 it purchased the San Rafael Corporate Center for $116.5 million. It is currently building a three-story, 85,000-square-foot research and development facility at 791 Lincoln Ave. and a parking garage with 649 spaces at 788 Lincoln Ave.The company has five treatments currently on the market and many more in the pipeline. And in November, BioMarin purchased the Dutch biotech company Prosensa Holding N.V., which may give it the first approved treatment for Duchenne muscular dystrophy, a form of muscular dystrophy that worsens quickly.